Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if administering inhaled antibiotics directly into the lungs in conjunction with intravenous (IV) antibiotics leads to better outcomes and decreased recurrence of ventilator associated pneumonia (VAP) when compared to IV antibiotics alone.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wright State University
• Treatments: Anti-Bacterial Agents; Tobramycin; Vancomycin

Criteria

Inclusion Criteria:

1. Clinical Pulmonary Infection Score (CPIS) greater than or equal to 6

2. Intubated greater than or equal to 48 hours

3. Screened for possible eligibility

4. Bronchoscopy and bronchoalveolar lavage (BAL) or combicath performed

5. Started on empiric intravenous (IV) and inhaled antibiotics after BAL for suspected ventilator associated pneumonia (VAP)

6. > 104 Colony Forming Units (CFU) on BAL

Exclusion Criteria:

1. <18 years of age

2. Pregnant

3. Human Immunodeficiency Virus (HIV) or on chronic immunosuppressants

4. Absolute Neutrophil Count <1,000

5. Allergy to vancomycin or tobramycin

6. Anaphylaxis to penicillin

7. Cystic Fibrosis

8. Previous enrollment

9. Creatinine >2 mg/dl or doubled within the previous 72 hours